Ascendis Pharma Growth Disorders A/S: Financial statements 2020
CVR: 32323677
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
Ascendis Pharma Growth Disorders A/S (CVR 32323677) has filed annual accounts for 2020. In 2020, the company reported a gross profit of EUR -30,184,950 and a net result of EUR -32,098,569 compared with EUR -19,025,880 the year before. Equity in the 2020 report amounted to EUR -89,483,905.
- Gross Profit
- EUR -30,184,950
- Profit/Loss
- EUR -32,098,569
- Equity
- EUR -89,483,905
- Total Assets
- EUR 10,730,677
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | -30.2M EUR | -32.1M EUR | -89.5M EUR | 0 |
| 2019 | - | -17.9M EUR | -19M EUR | -57.4M EUR | 0 |
| 2018 | - | -14.4M EUR | -15.3M EUR | -38.4M EUR | 0 |
| 2017 | - | -13.2M EUR | -13.7M EUR | -23M EUR | 0 |
| 2016 | - | -5.9M EUR | -6.1M EUR | -9.3M EUR | - |
Official annual report
How creditworthy is Ascendis Pharma Growth Disorders A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
Ascendis Pharma Growth Disorders A/S has published its annual report for 2019. Gross profit came to DKK -17,880,176, and the net result was DKK -19,025,880.
About Ascendis Pharma Growth Disorders A/S
Ascendis Pharma Growth Disorders A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ASCENDIS PHARMA, CIRCULATORY DISEASES DIVISION A/S and ASCENDIS PHARMA RELAXIN DIVISION A/S. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR -190,726,000 and a net result of EUR -225,725,000 compared with EUR -176,019,000 the year before. Equity in the 2025 report amounted to EUR -723,740,000.
